List of Figures
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 14
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2017* 15
Proportion of Homozygous Familial Hypercholesterolemia (HoFH) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2017* 16
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 18
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 19
Proportion of Homozygous Familial Hypercholesterolemia (HoFH) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2017* 20
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 22
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 23
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 24
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 25
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 26
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 27
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 28
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 29
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 30
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 32
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 34
GlobalData Methodology 104


List of Tables
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, Global, Clinical Trials by Region, 2017* 7
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 14
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 15
Proportion of Homozygous Familial Hypercholesterolemia (HoFH) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2017* 17
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 18
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 19
Proportion of Homozygous Familial Hypercholesterolemia (HoFH) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2017* 21
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 22
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 23
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, Global, Clinical Trials by Phase, 2017* 24
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 25
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 26
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 27
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 28
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 29
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 31
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 33
Homozygous Familial Hypercholesterolemia (HoFH) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 34